News Releases

Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences

November 8, 2023
REDWOOD CITY, Calif. , Nov. 08, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023

November 2, 2023
REDWOOD CITY, Calif. , Nov. 02, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria

Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer

September 25, 2023
Jeet Mahal Continues as COO REDWOOD CITY, Calif. , Sept. 25, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic
Displaying 1 - 10 of 39
Top

External Link

You are now leaving the Jasper Therapeutics, Inc. site to a 3rd party website. Jasper Therapeutics is not responsible for 3rd party website content.